about
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study.Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.Field Cancerization in Sporadic Colon Cancer.A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor.Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients.A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models.The significance of the trial outcome was associated with publication rate and time to publication.Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.Practice Patterns Regarding Multidisciplinary Cancer Management and Suggestions for Further Refinement: Results from a National Survey in Korea.Skin necrosis after a low-dose vasopressin infusion through a central venous catheter for treating septic shock.A rare case of acute leukemic presentation of blastic plasmacytoid dendritic cell neoplasm without cutaneous lesions.Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery.Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer.Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience.Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma.Peri-tumor administration of 5-fluorouracil sol-gel using a hollow microneedle for treatment of gastric cancer.Aggressive classical Kaposi's sarcoma mimicking malignant lymphoma.Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancerPrognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative ResectionRisk factors for incident anemia of chronic diseases: A cohort study[Outcome of intensive medical treatments in patients with infected severe necrotizing pancreatitis]Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinomaSerum CA 19-9 as a prognostic factor in patients with metastatic gastric cancerImproving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institutionRamosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and VomitingTreatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
P50
Q33408000-045C4AD7-9D20-4B2A-BDAF-C100E89D426CQ33425887-28F370AB-1A33-49B1-89D7-E6E552C3E13BQ33914265-159B092F-EA00-40B0-BE51-786DF1119984Q34039184-2A2CA85D-D0D8-4484-A8C8-559E84AA9C2FQ34326604-F5D2B0F5-F477-4A36-BA7D-4D82B73C73F4Q35590607-C7EB1049-E83E-4590-AC20-BA7E6B3DD351Q37213553-F1345563-2D39-4E0D-8A9C-6AD04A6EBF55Q37222532-03EBAFC8-6B0F-4329-A3B3-541E319BC255Q37367438-28B6B639-F261-4C8F-8175-1D729A73E59FQ38467530-7781AE69-4696-4D4A-B210-6DE923F50977Q38477495-05748DCC-CCC8-43B2-B1BA-396879DC7915Q38941324-41827C91-5C50-464D-AFFB-70FE1C3BAB5DQ40189187-8F16B84B-D16D-4E93-95B1-1EB9A6E572A6Q40321818-E6FCDC8E-CDE6-4A76-981F-633ACE0653FFQ41870294-F4C151AB-6AFA-42AE-8FD4-A37569AB56A9Q42415063-A8123BD4-65D7-4EF4-B0ED-63DF15EC495AQ44907228-7D251218-361C-4BA1-AE75-1CA5CBB9BE25Q45785151-85D8BD75-D7A2-45BD-A636-282FBF15B39EQ45897968-432D498E-3D3F-4F25-B8EE-AC8CCF60A3D5Q48447176-85166647-52BC-48F9-BA91-F1D0B01D4283Q48860696-E4B6FCCE-7B98-425B-A14C-710CA96244DBQ50090476-8B359573-BC68-420B-8590-D29B02DD6D70Q50586934-916D09D3-544D-4745-AFA5-259A83EDBE3EQ50707118-0CD87C89-C2FF-4596-BD17-417B2DABC464Q51375574-05377B03-B6A4-4A80-A3F8-AC34570FDE68Q51390058-D1195E43-60FE-4D3D-9E9F-D71CBF8DE221Q52722299-69A6428B-9B0D-41C2-AA18-4D5C3B652FF1Q53155775-F5A69A4B-5C65-43DC-B9CD-DB149C9CA3F7Q53600525-D6D3114A-AFC0-44BB-978D-63A07E15690CQ54308033-81A9E19B-2A0D-49D3-BA57-6362F96DC133Q55070104-5AF48799-7360-4082-97EC-CB5DB61F2A3BQ57212935-D2977A24-DE24-4738-AAF7-66190C07EDBEQ58098155-AC6E8E48-046B-4DC8-ABCF-056A38878592Q64066013-C228712F-37F4-4ADA-BE42-AD46B92EBA46Q79390100-747381C6-89F9-4334-86FA-6FB76EF2188BQ79507992-0A054B20-8D4E-4EEC-8F1D-2E226C6DE57BQ85515183-22EE8327-466F-434E-9F92-B1A5F9C14A25Q87885346-FC97AAB7-FFFF-4830-A199-E8599438E533Q90463022-6F0B9E47-0AA2-4654-B7C4-0942E2C4806AQ90749501-34B26AB6-1889-48A5-A8E2-0B12B218E168
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Dong-Hoe Koo
@ast
Dong-Hoe Koo
@en
Dong-Hoe Koo
@es
Dong-Hoe Koo
@nl
Dong-Hoe Koo
@sl
type
label
Dong-Hoe Koo
@ast
Dong-Hoe Koo
@en
Dong-Hoe Koo
@es
Dong-Hoe Koo
@nl
Dong-Hoe Koo
@sl
prefLabel
Dong-Hoe Koo
@ast
Dong-Hoe Koo
@en
Dong-Hoe Koo
@es
Dong-Hoe Koo
@nl
Dong-Hoe Koo
@sl
P106
P31
P496
0000-0001-9913-8883
P569
2000-01-01T00:00:00Z